Sana Biotechnology, Inc. (NASDAQ:SANA) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Sana Biotechnology, Inc. (NASDAQ:SANA) have earned a consensus recommendation of “Moderate Buy” from the nine research firms that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $9.3333.

Several equities analysts have weighed in on SANA shares. Weiss Ratings upgraded Sana Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 23rd. Rodman & Renshaw initiated coverage on Sana Biotechnology in a report on Monday, May 11th. They set a “buy” rating and a $16.00 price objective on the stock. Bank of America cut their price objective on Sana Biotechnology from $7.00 to $6.00 and set a “buy” rating on the stock in a research note on Friday, August 14th. Finally, Wall Street Zen downgraded shares of Sana Biotechnology from a “hold” rating to a “sell” rating in a report on Monday, July 20th.

Hedge Funds Weigh In On Sana Biotechnology

Several large investors have recently made changes to their positions in the business. Walleye Capital LLC bought a new stake in shares of Sana Biotechnology in the second quarter valued at approximately $35,000. Royal Bank of Canada raised its stake in Sana Biotechnology by 76.8% during the 1st quarter. Royal Bank of Canada now owns 12,285 shares of the company’s stock valued at $35,000 after purchasing an additional 5,338 shares during the last quarter. Mercer Global Advisors Inc. ADV bought a new stake in Sana Biotechnology in the 3rd quarter valued at $36,000. Rockefeller Capital Management L.P. increased its holdings in shares of Sana Biotechnology by 74.3% during the 4th quarter. Rockefeller Capital Management L.P. now owns 9,588 shares of the company’s stock worth $39,000 after purchasing an additional 4,088 shares during the period. Finally, Russell Investments Group Ltd. acquired a new position in shares of Sana Biotechnology during the third quarter valued at about $39,000. Institutional investors and hedge funds own 88.23% of the company’s stock.

Sana Biotechnology Stock Performance

NASDAQ:SANA opened at $3.74 on Friday. The company has a market capitalization of $1.12 billion, a P/E ratio of -4.92 and a beta of 2.16. The stock’s 50 day moving average price is $3.45 and its 200 day moving average price is $3.42. Sana Biotechnology has a 52 week low of $2.61 and a 52 week high of $6.55.

Sana Biotechnology (NASDAQ:SANA) last posted its earnings results on Tuesday, August 11th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.02. As a group, sell-side analysts forecast that Sana Biotechnology will post -0.57 earnings per share for the current fiscal year.

About Sana Biotechnology

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.